Various chemotherapeutic agents have been shown to increase, and ISG15 expression has been shown to be associated with tumor response to IFN-α treatment, chemotherapy, and radiotherapy [158, 159], as well as the survival of patients with acute promyelocytic leukemia, ovarian cancer, or breast cancer [21, 110]. Here, ISG15 is linked to neoplasm.